Clinical Trial Update: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing fulvestrant and anastrozole in hormone receptor-positive breast cancer. Results were posted in May 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Hormone Receptor Positive Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-05-17